Live CME Events Slide Library Webcasts Abstract Library LiverQ Academy Conference Highlights ☰

Target Audience:

This activity has been designed to meet the educational needs of healthcare providers involved in the care of patients with Cirrhosis.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Describe the importance of early detection of liver disease and current recommendations for disease screening and monitoring
  • Discuss the rationale for using albumin in the treatment of cirrhotic complications and summarize current treatment guidelines
  • Analyze recent and emerging data on the long-term use of albumin to prevent complications in patients with decompensated cirrhosis

Provided by

Supported by an educational grant from Grifols.

AGENDA

Welcome, Introduction, Learning Objectives
Marcelo Kugelmas, MD


Case Study
Sammy Saab, MD, MPH


Albumin Overview and Rationale for Use in CLD
Sammy Saab, MD, MPH


Data on Albumin Use in Cirrhosis
Marcelo Kugelmas, MD


Review of AASLD Guidelines
Marcelo Kugelmas, MD


Closing Remarks/Recommendations
Sammy Saab, MD, MPH


Q&A

Marcelo Kugelmas, MD, FACP, FAASLD

South Denver Gastroenterology, PC
Englewood, Colorado

Faculty Disclosures

Speaker: AbbVie Inc., Gilead Sciences, Inc., Echosens, Intercept Pharmaceuticals, Inc.

Consultant/Advisor: AbbVie Inc., Gilead Sciences, Inc., Echosens, Madrigal Pharmaceuticals, Inc., Topography Health, Inc., Intercept Pharmaceuticals, Inc.

Advisory Board: AbbVie Inc., Gilead Sciences, Inc., Echosens, Intercept Pharmaceuticals, Inc., Madrigal Pharmaceuticals, Inc.

Grant/Research: Madrigal Pharmaceuticals, Inc., Genentech, Inc., Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Ionis Pharmaceuticals, 89bio, Inc., Akero Therapeutics, Inc., GENFIT, Viking Therapeutics, NorthSea Therapeutics, Celgene Corporation, Enanta Pharmaceuticals, HighTide Therapeutics Inc., Novartis, Tobira Therapeutics.

Sammy Saab, MD, MPH

David Geffen School of Medicine at UCLA
Los Angeles, California

Faculty Disclosures

Speaker: AbbVie Inc., Gilead Sciences, Inc., Salix Pharmaceuticals, Inc.,Exelixis, Inc., and Dova Pharmaceuticals, Inc.

Consultant/Advisor: AbbVie Inc., Gilead Sciences, Inc., Mallinckrodt Pharmaceuticals.